Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Clinical Trial Not Allowed)
ID: 344626Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/344626

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-051.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Clinical Trial Not Allowed)." This initiative aims to explore the molecular mechanisms that connect dietary factors and lipid metabolism to cancer growth and progression, emphasizing the need for interdisciplinary research that bridges nutrition and molecular metabolism. The program is particularly focused on understanding how dietary variations, such as high-fat or ketogenic diets, influence lipid metabolism in cancer and their implications for tumor biology and patient outcomes. Eligible applicants can receive up to $500,000 per year for a project period of up to five years, with applications accepted until October 23, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-051.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-051-Full-Announcement.html
    PAR-23-051.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting applications under Funding Opportunity Announcement PAR-23-051. The initiative aims to investigate the mechanisms linking diet, lipid metabolism, and tumor growth/progression without the inclusion of clinical trials. It seeks to unite the fields of nutrition and molecular metabolism and promote research that addresses the complexities of lipid biochemistry. Funding is available for projects that explore how dietary variations affect lipid metabolism in cancers, particularly with high-fat or ketogenic diets, and their implications on tumor biology and patient outcomes. Eligible applicants include various institutions and organizations, with a maximum budget of $500,000 per year for a five-year project period. The application deadlines span from January 2023 to October 2025, with the research encouraged to tackle questions about the interplay between dietary components, lipid metabolism, tumor growth, and the tumor microenvironment. The NIH emphasizes the importance of incorporating nutrition expertise in research teams, collaboration, and data sharing to foster a multidisciplinary approach in understanding cancer metabolism in the context of dietary influences.
    Similar Opportunities
    Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for a funding opportunity titled "Mechanistic links between diet, lipid metabolism, and tumor growth and progression," under the UH2 Clinical Trial Not Allowed activity code. This initiative aims to support fundamental studies that investigate the molecular mechanisms linking lipid metabolism to tumor growth, with a focus on bridging the fields of nutrition and molecular metabolism. The program is particularly significant as it addresses critical gaps in understanding the relationship between diet and cancer biology. The funding amount is capped at $275,000 over a two-year period, with applications due by October 23, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research investigating the mechanisms by which bariatric surgery impacts cancer risk, under the title "Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)." This initiative aims to support studies that explore the long-term effects of bariatric surgery on cancer risk, moving beyond immediate outcomes such as weight loss and diabetes, and considering factors like sex, racial background, and procedure type. With a funding ceiling of $500,000 per year for up to five years, the program encourages innovative research proposals from a diverse range of eligible applicants, including educational institutions and community organizations. Applications are due by January 7, 2028, and interested parties can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-043.html.
    Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)." This grant aims to support innovative, investigator-initiated studies that explore how bariatric surgery influences cancer risk, moving beyond traditional short-term outcomes such as weight loss and diabetes management. Given the rising prevalence of obesity and the increasing number of bariatric surgeries performed in the U.S., this research is crucial for identifying new pathways for cancer prevention. The grant provides funding of up to $275,000 over two years, with applications due by January 16, 2025, and additional cycles available through 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-044.html.
    Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 exploratory research grant titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics." This grant aims to support preclinical and patient-based studies that investigate how incretin mimetics, specifically GLP-1 and GIP-1 receptor agonists, influence cancer risk, particularly in relation to obesity-related cancers such as thyroid and prostate cancers. The funding, which amounts to a maximum of $275,000 over two years, is intended for projects that do not involve clinical trials, with applications opening in January 2024 and a submission deadline of January 7, 2027. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)" aimed at investigating how incretin mimetics, particularly GLP-1 and dual GLP-1/GIP-1 receptor agonists, influence cancer risk. The program seeks to promote preclinical and patient-based studies that explore the mechanisms by which these agents affect cancer, especially in relation to obesity-related cancers, while attracting talented scientists to focus on long-term outcomes rather than short-term effects like weight loss and diabetes. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and foreign entities, with applications encouraged to begin submission starting January 5, 2024, for projects with a funding period of up to five years. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and the opportunity is set to close on January 7, 2027.
    Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)." This initiative invites applications aimed at improving the utility of mammalian cancer models, including organoids and tumoroids, to better represent human biology and address translational deficiencies in existing models. The funding seeks to advance cancer research by fostering innovative approaches to validate these models and enhance their clinical relevance, ultimately aiming to improve patient outcomes. Eligible applicants can receive up to $499,000 per year for a maximum of five years, with applications due by September 7, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-281.html.
    The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the Metastasis Research Network (MetNet), inviting applications for U01 Research Projects that utilize systems-level approaches to advance understanding of cancer metastasis. The initiative aims to address critical gaps in metastasis research, focusing on themes such as cancer dormancy, early dissemination, and the interactions within the metastatic environment. This funding is vital for fostering collaborative research efforts that can lead to improved treatment outcomes for cancer patients. Eligible applicants include a diverse range of institutions, with a maximum funding limit of $500,000 per year for up to five years. Applications are due by June 20, 2025, and interested parties can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed)" aimed at advancing research on RNA modifications that contribute to cancer development. This initiative seeks to support collaborative projects that explore the mechanistic roles of mRNA, tRNA, and rRNA modifications in translational reprogramming during tumor initiation and progression, emphasizing the need for a multi-principal investigator approach to address the complex interactions of these modifications. The NIH plans to fund up to five U01 grants with a total budget of $4.9 million, and applications are due by November 4, 2024. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-029.html.
    Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer," aimed at supporting exploratory research into the human microbiome's role in anti-tumor immunity. This initiative seeks to elucidate the mechanisms by which specific microbes or their metabolites influence immune responses and inflammation related to tumor formation, with a focus on identifying novel molecular targets for cancer prevention strategies. Eligible applicants include a wide range of organizations, such as educational institutions, nonprofits, and tribal governments, with funding available up to $275,000 for two-year projects. Interested parties should submit their applications by January 7, 2025, and can find additional information at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes" (PAR-23-254). This initiative aims to encourage researchers to conduct innovative analyses of existing datasets, including clinical, genomic, and epidemiological data, to address critical questions related to cancer risk, treatment responses, and health outcomes. By leveraging previously collected data, the program seeks to enhance understanding of cancer-related issues while allowing for a limited generation of new data for validation purposes. Eligible applicants include a wide range of institutions, with funding capped at $350,000 annually for up to five years. Applications will be accepted from October 2023 until June 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.